A NEW ASYMMETRIC METHOD FOR THE SYNTHESIS OF RIVASTIGMINE HYDROGEN TARTRATE, CRYSTAL FORM TYPE II, ITS IMPLEMENTATION FOR PREPARING ORAL SOLUTION FOR THE TREATMENT OF DEMENTIA AND DEPENDENCES

摘要

This invention brought a new, rapid and convenient method for industrial synthesis of (S)-3-[1 -(dimethylamino)ethyl]phenyl-N-ethyl-N-methyl-carbamate hydrogen-(2R, 3R)-tartrate (Rivastigmine Hydrogen Tartrate), crystal form Type II, as well as its use for the manufacture of an oral solution with water clusters, stabilized in 4D mM citrate buffer for the treatment of dementia associated with Alzheimer's and Parkinson's disease and for severe addictions from smoking and drugs. In the present invention presented a stabilized pharmaceutical composition of the oral solution of rivastigmine hydrogen tartrate, stabilized in citric acid / sodium citrate buffer of 40mM capacity with water clusters useful for the treatment of dementia associated with Alzheimer's and Parkinson's disease and for severe addictions from smoking and drugs.